Page 34 - Bio Developments News Today

The White House releases a report detailing how it will harness biotechnology and biomanufacturing to address numerous societal challenges, including human health.

Remedium Bio, a US biotech, and Exothera, a Belgian CDMO, have established a collaborative agreement in relation to the US firm’s disease modifying gene therapy for osteoarthritis, AAV2-FGF18.

The new Clinical Biotechnology Centre (CBC) in Bristol will expand the UK’s ability to make clinical grade products for the research and development of new cell and gene therapies.

MRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range from embracing AI to a 'bold campaign' of cancer vaccine studies.

Intergalactic Therapeutics, a startup focused on non-viral gene therapy, reports positive preclinical results for its lead program, IG-002, addressing all forms of ABCA4-related retinopathies.

The developer of oral vaccines announces a restructure of its business priorities, as it looks to conserve cash to progress its norovirus candidate.

BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications.

Charles River and La Jolla Institute for Immunology (LJI) are collaborating on a new project to uncover how different cells in the human immune system respond to SARS-CoV-2 in early, acute infection.

Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a ‘vaccinal effect’ for the treatment of HIV and prevention of malaria.

Poolbeg Pharma has in-licenced a novel, intra-nasal RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick.